Lead Product(s): OVX836
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: European Innovation Council
Deal Size: $34.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 08, 2020
The grant willsupport the completion of the Company’s Phase 2a immunogenicity clinical trial for OVX836, its lead universal flu vaccine candidate and the early discovery phase for its universal coronavirus vaccine program.